PRL-3 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PRL-3 Inhibitor | 893449-38-2 | sc-222189 | 10 mg | $280.00 | 1 | |
The chemical "PRL-3 Inhibitor" (CAS 893449-38-2) is a compound specifically designed to inhibit the activity of PRL-3 (Phosphatase of Regenerating Liver 3), an enzyme known for promoting tumor growth, invasion, and metastasis. By targeting PRL-3, this inhibitor modulates its function, potentially impacting cellular signaling pathways involved in cancer progression. | ||||||
NSC 87877 | 56990-57-9 | sc-204139 | 50 mg | $134.00 | 12 | |
NSC-87877 is a dual inhibitor of Shp2 and PRL-3 phosphatases. By inhibiting PRL-3, it prevents the dephosphorylation of its substrates, which can disrupt signaling pathways involved in cellular proliferation and migration. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $148.00 | 104 | |
S3I-201 inhibits the Stat3 pathway. PRL-3 can upregulate the Stat3 pathway, so inhibiting this pathway with S3I-201 can indirectly downregulate PRL-3 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets Raf kinases and VEGFRs. By inhibiting these pathways, Sorafenib can indirectly downregulate PRL-3, as PRL-3 is known to enhance the activation of the Raf/MEK/ERK pathway. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor, which can inhibit the PI3K/Akt pathway. Given that PRL-3 can activate the PI3K/Akt pathway, inhibiting this pathway with Sunitinib can indirectly downregulate PRL-3 activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. PRL-3 can upregulate EGFR signaling, so inhibiting this pathway with Erlotinib can indirectly downregulate PRL-3 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. By inhibiting Src family kinases, which can be activated by PRL-3, Dasatinib can indirectly downregulate PRL-3 activity. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor. By inhibiting the MEK1/2 kinases, Selumetinib can indirectly downregulate PRL-3 activity, as PRL-3 is known to enhance the activation of the Raf/MEK/ERK pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting proteasome function, Bortezomib can indirectly downregulate PRL-3 activity, as PRL-3 is degraded by the proteasome. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor. By inhibiting the JAK/STAT pathway, Ruxolitinib can indirectly downregulate PRL-3 activity, as PRL-3 can upregulate the Stat3 pathway. | ||||||